THE CURELINE GROUP and Cellecta Inc LAUNCH TISSUE TO TARGET STRATEGIC PARTNERSHIP INITIATIVE

Updated: Oct 1, 2022

THE CURELINE GROUP and Cellecta Inc LAUNCH TISSUE TO TARGET STRATEGIC PARTNERSHIP INITIATIVE

Brisbane, CA, and Mountain View, CA–(PRNewswire)–October XX, 2022

The Cureline Group and Cellecta, Inc. today announced the launch of Tissue to TargetTM a new strategic partnership to combine the companies’ core strengths in human biospecimen management and specialty lab services with a focus on immuno-oncology and auto-immune disease.

The Tissue to Target partnership will improve efficiency, cost and time to completion of early-phase clinical trials and translational medicine programs by leveraging the Cureline Group’s proven foundation in human biospecimen management with Cellecta’s renowned capabilities in functional genomics techniques for drug target and biomarker discovery and validation. Together, these two companies provide the highest level of expertise to facilitate evidence-based decision-making and superior clinical research outcomes.

“I am very excited about our new partnership with Cellecta. Cureline global capabilities in HBS management and Cellecta exceptional assay development expertise will provide new great opportunities to our clients working on human disease biomarker R&D”

Olga Potopova, Ph.D., CEO, CURELINE Group

“Cellecta is pleased to partner with the Cureline Group in enabling a streamlined workflow for translational medicine projects and early-stage clinical trials. With long-standing experience as a custom service provider of molecular and cell biology-based assays, including the DriverMap TM Adaptive Immune Repertoire Assay, Cellecta has enabled thousands of researchers in the pharmaceutical, biotechnology and academic sectors to achieve their discovery and development goals. Working with us, researchers benefit from synergies that will empower them to fast-track to successful outcomes.”

Alex Chenchik, Ph.D., Cellecta president and chief scientific officer

The Tissue to Target partnership will provide researchers with access to a complete workflow including sample collection and management, best-in-class assays for drug and biomarker target discovery and validation, and initial data analysis. Together, the Cureline Group and Cellecta Inc. will ensure that all early-phase trial needs are met, enabling researchers to focus more on hitting study goals and milestones.

About The Cureline Group:

The Cureline Group has been providing human biospecimen and laboratory processing services for clinical trials since 2003. Its global clinical network and exceptional staff ensure efficient access to both standard and customized products for precision medicine and translational research, wherever you are in the world. Platform flexibility, cost-effectiveness and optimizing solutions: that’s the Cureline promise. (www.curelinegroup.com)

About Cellecta Inc.:

Cellecta, Inc., a trusted provider of genomic products and services, is an industry leader in RNAi and CRISPR technologies as well as targeted RNA-sequencing technologies for the discovery and characterization of novel therapeutic targets and genetic profiling for drug and biomarker discovery and validation. Over 400 scientific papers have been published citing Cellecta’s functional genomics portfolio. Cellecta, Inc. is headquartered in Mountain View, California. Further information about the company and its functional genomic products and services may be found at www.cellecta.com. (www.cellecta.com)